M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”.

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis – JAMA

Editorial: IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How? – JAMA

Commentaries: Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients – King’s College London AND WHO advises 2 monoclonal antibodies for severe COVID – CIDRAP

Commentary on Twitter (thread – click for more)

1/n
Here we go –
Our paper assessing the role of interleukin-6 antagonists treatments in the management of COVID-19 patients?https://t.co/AJErHypx9a@WHO @jonathanasterne @diazjv @JAMA_current @KCLImmunoMicro @GSTT_ICU @GSTTresearch

— Manu Shankar-Hari (@msh_manu) July 6, 2021